Market capitalization | $5.47b |
Enterprise Value | $5.45b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 15.03 |
P/S ratio (TTM) P/S ratio | 15.09 |
P/B ratio (TTM) P/B ratio | 17.05 |
Revenue growth (TTM) Revenue growth | 60.80% |
Revenue (TTM) Revenue | $362.80m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
19 Analysts have issued a Blueprint Medicines Corp. forecast:
19 Analysts have issued a Blueprint Medicines Corp. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 363 363 |
61%
61%
|
|
Gross Profit | 332 332 |
83%
83%
|
|
EBITDA | -341 -341 |
32%
32%
|
EBIT (Operating Income) EBIT | -356 -356 |
32%
32%
|
Net Profit | -205 -205 |
63%
63%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Kathryn Haviland |
Employees | 655 |
Founded | 2008 |
Website | www.blueprintmedicines.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.